Study evaluates if adding a post-transplant drug to standard glioblastoma treatment of radiation therapy and chemotherapy helps overcome tumor resistance

The Alliance for Clinical Trials in Oncology has activated a new clinical trial (Alliance A072402) for people with brain cancer. The study is evaluating whether adding a drug typically used in the post-transplant setting to the standard regimen of radiation therapy and chemotherapy can improve survival for people with newly diagnosed glioblastoma, the most common type of cancerous brain tumor.

Led by Study Co-Chairs Priya Kumthekar, MD, Professor of Neurology and Hematology/Oncology at Northwestern University Feinberg School of Medicine in Chicago, and Yoshie Umemura, MD, MS, Chief of Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, and Chief Medical Officer of Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, this Phase 2/3 study investigates whether targeting a distinct metabolic vulnerability in glioblastoma cells by adding mycophenolate mofetil can help overcome tumor resistance to standard chemoradiation.

“Glioblastoma quickly learns how to resist standard treatments, often leaving patients with far too few options,” said Dr. Kumthekar. “Because glioblastoma cells rely on a specific fuel-building process that healthy brain cells largely don’t need, we hope that adding mycophenolate mofetil will allow us to cut off that fuel supply, slowing tumor growth and helping radiation and chemotherapy work more effectively.”

Glioblastoma is the most common and aggressive primary malignant brain tumor in adults, and it remains difficult to treat, with only about 7 percent of patients surviving five years after diagnosis. According to the Glioblastoma Foundation, about 14,000 new cases of glioblastoma are diagnosed annually in the United States, accounting for about half of all primary malignant brain tumors.

Research shows that glioblastoma cells rely on specific energy and building processes. While healthy brain cells recycle existing building blocks (called purines) to function, glioblastoma cells rapidly manufacture new cells from scratch to fuel their fast growth. In animal studies, researchers have shown that mycophenolate mofetil’s ability to block the key enzyme IMPDH needed for making new glioblastoma cells can slow the tumor’s ability to grow.

Earlier laboratory studies have shown that adding mycophenolate mofetil to radiation and chemotherapy makes those treatments work even better together. In addition, early results from two smaller human clinical trials have found that mycophenolate mofetil can cross the brain’s protective barrier, hit its intended target in the tumor when given alongside standard care, and is will well tolerated with standard treatments.

“Previous studies have shown that mycophenolate mofetil can reach the brain and block the exact process that helps these tumors grow,” said Dr. Umemura. “Because this is already a safe, widely available, and affordable pill, if this trial is able to show that it helps patients live longer, we could make it a standard part of care quickly.”

Sponsored by the National Cancer Institute and conducted by the Alliance for Clinical Trials in Oncology, Alliance A072402 plans to enroll 422 adults in a randomized clinical trial, the gold standard in medical research, to determine if adding mycophenolate mofetil to radiation and chemotherapy improves survival for people with this hard-to-treat cancer.

In this study, adults aged 18 and older with newly diagnosed primary glioblastoma who have not received prior therapy beyond surgical resection will be randomly assigned to one of two treatment arms:

  • Control arm (standard of care): Patients receive standard radiation therapy alongside the daily oral chemotherapy drug temozolomide, followed by a four-week rest period and up to six 28-day maintenance cycles of temozolomide.
  • Experimental arm: Patients receive the same standard radiation and temozolomide regimen combined with twice-daily oral mycophenolate mofetil during chemoradiation and throughout the six maintenance cycles.

The trial’s primary objective is to compare progression-free survival in the Phase 2 portion and overall survival in the Phase 3 portion between patients receiving mycophenolate mofetil plus standard therapy and those receiving standard therapy alone. Secondary objectives include comparing objective tumor response rates, evaluating side effects, and assessing the association between overall survival and progression-free survival across treatment arms.

Reference: Mycophenolate Mofetil to Overcome Glioblastoma Resistance to Radiotherapy and Temozolomide, https://clinicaltrials.gov/study/NCT07605364

###

The Alliance for Clinical Trials in Oncology is a national leader in advancing cancer research, uniting more than 26,000 cancer specialists at 112 main institutions and nearly 1,500 affiliates across the U.S. and Canada. As part of the National Clinical Trials Network and a leading research base for the NCI Community Oncology Research Program, the Alliance conducts pioneering, practice-changing clinical trials that improve outcomes and reshape standards of care. Our work has led to multiple FDA approvals, influenced national guidelines, and produced hundreds of high-impact publications. Nearly 100,000 participants have taken part in Alliance studies, and our growing biospecimen repository now includes more than 1.5 million samples, collected over the past 30 years.